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descending coronary artery (LADCA) for the dose distribution for a left 
sided breast cancer patient. 
Materials and Methods: One left-sided breast cancer patient treated 
with adjuvant radiotherapy after a breast-conserving operation in 
November 2012 was chosen randomly. The patient was scanned with 
2.5 mm slice thickness without contrast. Oncentra® External Beam 
v3.3 (Nucletron, An Elekta Company) was used for delineation and 
planning (collapsed cone algorithm).The individual delineations (IDs) 
of the CTV, heart and LADCA were performed by six experienced 
radiographers and one experienced radiation oncologist according to 
our written clinical guidelines. Finally, two experienced radiographers 
and two radiation oncologists agreed on consensus delineation (CD) of 
all three volumes.The dice similarity coefficient (DSC) was used to 
evaluate the overlap accuracy between the CTV and the heart for 
each ID using the CD as a reference. Treatment plans for each of the 
seven IDs and the CD were optimised according to the clinical 
guidelines by one radiographer. The volume of the CTV receiving 95 % 
of the prescribed dose (50 Gy/25 fractions) or higher (V95%) and dose 
to heart and LADCA from each treatment plan were found for the CD 
structures. 
Results: The volumes of the CD CTV and heart were 664.5 cm3 and 
550.8 cm3, respectively. For the seven IDs the median value for the 
CTV and heart were 672.1 cm3 (range 641.4 – 692.5 cm3) and 546.7 
cm3 (539.9 – 561.5 cm3), respectively. Median values of DSC for the 
CTV and heart were 0.96 (0.94 – 0.98) and 0.97 (0.95 – 0.98), 
respectively. All ID structures were delineated in the same slices as 
the CD ± one slice except for one LADCA delineation that differed by 
two slices. Delineations in one slice are shown in Figure 1. For the 
seven treatment plans, the median V95% for the ID CTVs was 97.8 % 
(97.3 – 98.0 %). Evaluation of dose to CTV as defined on the CD from 
each of the seven treatment plans resulted in a median V95% of 97.9 % 
(97.8 – 98.0). Dose constraints for the heart (V20Gy<10 %, V40Gy<5%) and 
LADCA (Dmax<20 Gy) were not violated in any of the seven treatment 
plans. 
Conclusions: The results of DSC for the delineated CTV and OARs for a 
left sided breast cancer patient show only a slight variation in 
delineation. No clinical relevant differences in delineation of CTV 
were seen between radiographers and the oncologist when using the 
same clinical guidelines. This is believed to be due to precisely 
described guidelines and education. Furthermore the small variations 
in delineations is believed to have no clinical influence on the 
treatments as seen from the very small differences in dose coverage 
for the CD CTV as well as the dose to the CD OARs in the treatment 
plans based on the IDs. 
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Purpose/Objective: In early breast cancer patients conservative 
therapy followed by whole breast radiotherapy (WBI) offers a good 
quality of life (QoL). Although partial breast irradiation (PBI) is 
increasingly used as an alternative to WBI in selected groups of 
patients, its impact on QoL has not been extensively studied. This 
study assessed patients’ QoL after PBI with high-dose rate interstitial 
brachytherapy (BRT) compared with WBI.  
Materials and Methods: QoL was evaluated in 39 PBI patients, 
enrolled in a phase II prospective study (32 Gy in two daily fractions 
over 4 days) and in 78 matched WBI controls (50 Gy standard 
fractionation ± 10 Gy boost). Ten-item self-administered close-
response questionnaire, exploring body image, fear of recurrence, 
satisfaction with treatment and cosmetic results, was administered 
twice during follow-up at a mean of 20 and 80 months after 
treatment. Italian version of questionnaire was asseverated. 
Physicians’ and patients’ cosmetic assessments were compared. 
Chemotherapy and hormonal therapy effect on cosmetics was 
analysed. The Mann-Whitney test and Wilcoxon test compared the 
results. The X2 test was used for categorical data. For concordance 
between judgements was used Cohen’s k-test of inter-rater 
agreement. Strength of agreement was interpreted according to the 
Landis and Koch’s gradation. P <0.05 was considered significant. 
Results: The two groups were well matched, except higher 
chemotherapy-treated patients in WBI group (41% vs 15%, p = 0.004). 
At first analysis no significant difference emerged on body image and 
fear of recurrence scales. PBI patients were more satisfied with 
treatment (p=0.019) and cosmetic outcome (p=0.0001). Second 
analysis included 96 patients, 33 in the PBI group, 63 in the WBI 
group. No significant differences were found on body image or fear of 
recurrence scales. Cosmetic outcome was better in PBI group 
(p=0.002). Results from the first and the second analysis were 
compared into each treatment group. Body image scale was 
significantly better at the first analysis in both groups (p=0.001 for 
PBI; p=0.0001 for WBI). Fear of recurrence scale was unchanged. No 
differences were found in cosmetic outcome as assessed by patients. 
In the first analysis physicians assessed cosmetic outcome as 
significantly better in PBI group (p= 0.0001) and confirmed it at 
second analysis. Physicians’ and patients’ opinions on cosmetics 
diverged (k = 0.148 at 2 years, 0.023 at 5 years) with physicians 
judging outcomes better than patients. Adjuvant chemotherapy had 
no impact of on cosmetics in either group according to physicians and 
patients.  
Conclusions: Even at longer follow-up, QoL is similar after BRT PBI or 
WBI in terms of body image, fear of recurrence and satisfaction with 
treatment; PBI provides a significantly better cosmetic outcome.  
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Purpose/Objective: The ICRU Report 83 suggests several methods to 
evaluate a PTV extending outside the contour of the body, ensuring an 
adequate treatment of the CTV volume. When Forward IMRT (F-IMRT) 
techniques are used, as is common in breast cases, tools like 
automatic fluence extension sometimes are not available. The 
purpose of this study was to analyse different approaches to correctly 
evaluate PTV dose in breast F-IMRT. 
Materials and Methods: We analyzed data from 40 patients 
undergoing radiotherapy after breast conserving surgery. The patients 
were submitted to a CT for virtual simulation with 3 mm slices. Target 
volumes were outlined: breast CTV and PTV (expansions of 10 mm 
were made for all directions except for the posterior one, which was 7 
mm). This PTV extends outside the body surface. Two sub-volumes of 
PTV were further established: a PTV-SV1, corresponding to the PTV 3 
mm inside the body, and a PTV-SV2, corresponding to the rest of the 
PTV (mostly air). Treatment plans were made with a forward IMRT 
technique using ELEKTA XiO 4.70 treatment planning system, with a 
superposition calculation algorithm. To each patient 3 dosimetric 
plans, to be delivered with a 6 MV SIEMENS Primus linac, were 
calculated according to the following situations:  
Plan 1. Using the delineated PTV extended outside the body surface. 
Plan 2. Extending the body surface to include all PTV volume. 
Plan 3. Same as Plan 2 but attributing a density to PTV-SV2 equal to 
the mean breast density. 
For each of these situations we evaluated the mean dose to PTV and 
PTV-SV1 according to the ICRU 83 Report. 
Results: We have obtained different results for each of the studied 
situations. In all approaches the Dmean to PTV-SV1 was similar to the 
prescription dose of 50Gy. However, only when a density was 
atributted to PTV-SV2 (Plan 3) the Dmean in PTV approached the 
prescription dose. 
